• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中国 42573 例肝切除术:多中心回顾性调查。

42,573 cases of hepatectomy in China: a multicenter retrospective investigation.

机构信息

Institute of Hepato-pancreato-bililary Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.

Cancer Hospital of Sun Yat-sen University, Guangzhou, 510060, China.

出版信息

Sci China Life Sci. 2018 Jun;61(6):660-670. doi: 10.1007/s11427-017-9259-9. Epub 2018 Feb 2.

DOI:10.1007/s11427-017-9259-9
PMID:29417360
Abstract

Hepatectomy is currently routinely performed in most hospitals in China. China owns the largest population of liver diseases and the biggest number of liver resection cases. A nationwide multicenter retrospective investigation involving 112 hospitals was performed, and focused on liver resection for patients with hepatocellular carcinoma (HCC). 42,573 cases of hepatectomy were enrolled, and 18,275 valid cases of liver resection for HCC patients were selected for statistical analysis. The epidemiology of HCC, distribution of hepatectomy, postoperative complications and prognosis were finally analyzed. In the 18,275 HCC patients, 81% had hepatitis B virus infection and 10% had hepatitis C virus infection. 38% of the HCC patients had normal Alphafetoprotein (AFP) level, and other 35% had an AFP level lower than 400 ng mL. In the study period, 97% of the hepatectomy for HCC were treated with open surgery, and 23.81% had vascular exclusion techniques. The operation time was (191.7±105.6) min, the blood loss was (546.0±562.8) mL, and blood transfusion was (543.0±1,035.2) mL. The median survival for HCC patients was 631 days, with 1-, 3-, and 5-year overall survival of 73.2%, 28.8% and 19.6%, respectively. Liver cirrhosis, multiple nodules, tumor thrombosis and high AFP level were risk factors that affect postoperative survival.

摘要

肝切除术目前在中国大多数医院常规进行。中国拥有最大的肝病患者人群和最大数量的肝切除术病例。进行了一项涉及 112 家医院的全国多中心回顾性调查,重点是肝细胞癌(HCC)患者的肝切除术。共纳入 42573 例肝切除术,其中 18275 例 HCC 患者的肝切除术有效病例用于统计分析。最终分析了 HCC 的流行病学、肝切除术的分布、术后并发症和预后。在 18275 例 HCC 患者中,81%有乙型肝炎病毒感染,10%有丙型肝炎病毒感染。38%的 HCC 患者甲胎蛋白(AFP)水平正常,另有 35%的 AFP 水平低于 400ng/mL。在研究期间,97%的 HCC 肝切除术采用开放手术,23.81%采用血管阻断技术。手术时间为(191.7±105.6)min,出血量为(546.0±562.8)mL,输血(543.0±1035.2)mL。HCC 患者的中位生存时间为 631 天,1、3 和 5 年总生存率分别为 73.2%、28.8%和 19.6%。肝硬化、多发结节、肿瘤血栓形成和高 AFP 水平是影响术后生存的危险因素。

相似文献

1
42,573 cases of hepatectomy in China: a multicenter retrospective investigation.中国 42573 例肝切除术:多中心回顾性调查。
Sci China Life Sci. 2018 Jun;61(6):660-670. doi: 10.1007/s11427-017-9259-9. Epub 2018 Feb 2.
2
[A new prognostic score system of hepatocellular carcinoma following hepatectomy].[一种肝切除术后肝细胞癌的新预后评分系统]
Zhonghua Zhong Liu Za Zhi. 2017 Dec 23;39(12):903-909. doi: 10.3760/cma.j.issn.0253-3766.2017.12.005.
3
Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients.术前甲胎蛋白和脱γ-羧基凝血酶原在肝细胞癌患者中的预后作用
World J Gastroenterol. 2015 Apr 28;21(16):4933-45. doi: 10.3748/wjg.v21.i16.4933.
4
High preoparative levels of serum periostin are associated with poor prognosis in patients with hepatocellular carcinoma after hepatectomy.术前血清骨膜蛋白水平高与肝癌患者肝切除术后预后不良相关。
Eur J Surg Oncol. 2013 Oct;39(10):1129-35. doi: 10.1016/j.ejso.2013.06.023. Epub 2013 Jul 31.
5
Survival outcomes of hepatectomy for stage B Hepatocellular carcinoma in the BCLC classification.巴塞罗那临床肝癌分期 B 期肝癌行肝切除术的生存结局。
World J Surg Oncol. 2017 Aug 22;15(1):156. doi: 10.1186/s12957-017-1229-x.
6
Hepatic resection and prognosis for patients with hepatocellular carcinoma larger than 10 cm: two decades of experience at Chang Gung memorial hospital.大于10厘米的肝细胞癌患者的肝切除与预后:长庚纪念医院二十年经验
Ann Surg Oncol. 2003 Nov;10(9):1070-6. doi: 10.1245/aso.2003.03.072.
7
Resection of hepatocellular carcinoma with tumor thrombus in the major vasculature. A European case-control series.伴有主要脉管系统肿瘤血栓的肝细胞癌切除术:一项欧洲病例对照研究系列
J Gastrointest Surg. 2006 Jun;10(6):855-62. doi: 10.1016/j.gassur.2005.12.011.
8
Nomogram for Preoperative Estimation of Microvascular Invasion Risk in Hepatitis B Virus-Related Hepatocellular Carcinoma Within the Milan Criteria.米兰标准范围内乙型肝炎病毒相关性肝细胞癌微血管侵犯风险的术前预测列线图。
JAMA Surg. 2016 Apr;151(4):356-63. doi: 10.1001/jamasurg.2015.4257.
9
Alpha fetoprotein changes predict hepatocellular carcinoma survival beyond the Milan criteria after hepatectomy.甲胎蛋白变化可预测肝切除术后超出米兰标准的肝细胞癌患者的生存率。
J Surg Res. 2017 Mar;209:102-111. doi: 10.1016/j.jss.2016.10.005. Epub 2016 Oct 14.
10
Mesohepatectomy for hepatocellular carcinoma: a study of 256 patients.肝细胞癌的肝中叶切除术:256例患者的研究
Int J Colorectal Dis. 2008 May;23(5):543-6. doi: 10.1007/s00384-007-0411-y. Epub 2008 Jan 9.

引用本文的文献

1
Optimizing Lidocaine Dosing in Hepatectomy Patients: A Population Pharmacokinetic Study of Active Metabolites.优化肝切除患者的利多卡因给药剂量:活性代谢物的群体药代动力学研究
Drug Des Devel Ther. 2025 Jul 22;19:6255-6268. doi: 10.2147/DDDT.S485389. eCollection 2025.
2
Prognostic utility of the global leadership initiative on malnutrition criteria in predicting outcomes after hepatectomy for hepatocellular carcinoma: a multicenter, retrospective study.全球营养不良领导倡议标准在预测肝细胞癌肝切除术后结局中的预后效用:一项多中心回顾性研究
Front Nutr. 2025 Jun 26;12:1610066. doi: 10.3389/fnut.2025.1610066. eCollection 2025.
3
A cost-effective predictive tool for AFP-negative focal hepatic lesions of retrospective study: enhancing clinical triage and decision-making.
一项用于AFP阴性局灶性肝病变回顾性研究的经济高效预测工具:加强临床分诊与决策制定。
PeerJ. 2025 Mar 26;13:e19150. doi: 10.7717/peerj.19150. eCollection 2025.
4
Factors associated with pulmonary complications after hepatectomy and establishment of nomogram: A real-world retrospective study.肝切除术后肺部并发症相关因素及列线图的建立:一项真实世界回顾性研究。
Indian J Anaesth. 2025 Feb;69(2):225-235. doi: 10.4103/ija.ija_885_24. Epub 2025 Jan 29.
5
Association of intratumoral microbiome diversity with hepatocellular carcinoma prognosis.肿瘤内微生物群多样性与肝细胞癌预后的关联
mSystems. 2025 Jan 21;10(1):e0076524. doi: 10.1128/msystems.00765-24. Epub 2024 Dec 11.
6
Comparison of the outcomes between ultrasonic devices and clamping in hepatectomy: a meta-analysis.超声设备与夹闭在肝切除术中效果的比较:荟萃分析。
World J Surg Oncol. 2024 Nov 16;22(1):304. doi: 10.1186/s12957-024-03575-3.
7
Serum CHI3L1 Levels Predict Overall Survival of Hepatocellular Carcinoma Patients after Hepatectomy.血清几丁质酶3样蛋白1水平可预测肝癌患者肝切除术后的总生存期。
J Cancer. 2024 Oct 14;15(19):6315-6325. doi: 10.7150/jca.100791. eCollection 2024.
8
The effect of CXCL12 on survival outcomes of patients with viral hepatitis-associated hepatocellular carcinoma after hepatectomy.CXCL12对病毒性肝炎相关肝细胞癌患者肝切除术后生存结局的影响。
Heliyon. 2024 May 7;10(9):e30782. doi: 10.1016/j.heliyon.2024.e30782. eCollection 2024 May 15.
9
Development of nanobodies targeting hepatocellular carcinoma and application of nanobody-based CAR-T technology.针对肝癌的纳米抗体的开发及基于纳米抗体的 CAR-T 技术的应用。
J Transl Med. 2024 Apr 12;22(1):349. doi: 10.1186/s12967-024-05159-x.
10
New insights in the metabolic function related to gut microbiota in the process of liver regeneration.肝脏再生过程中与肠道微生物群相关的代谢功能新见解。
Hepatobiliary Surg Nutr. 2023 Dec 1;12(6):933-935. doi: 10.21037/hbsn-23-508. Epub 2023 Oct 30.